The ever-changing nature of SARS-CoV-2 has highlighted the need for high-quality, rapid full genome sequencing. The CEVT Viral Genomics and Surveillance Lab uses Illumina platforms (MiSeq, NextSeq, and NovaSeq) to achieve a balance of rapidity and cost-effectiveness for SARS-CoV-2 full genome sequencing. The CEVT remains the top submitter of viral sequences from the state of Louisiana. The CEVT has partnered with local hospitals for sequencing of COVID-19 positive specimens and vaccine breakthrough cases. CEVT recently successfully competed for and was awarded two-year contract with Louisiana Department of Health for SARS-CoV-2 sequencing beginning in July 2021.For more information on LSU Health Shreveport’s sequencing program, please contact Dr. Krista Queen (Krista.Queen@lsuhs.edu), Director of the Viral Genomics and Surveillance Lab.